EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration.
John K. Field
(1, 2)
,
Triantafillos Liloglou
(1)
,
Asaf Niaz
(1)
,
J. Bryan
(1)
,
J. R. Gosney
(3)
,
T. Giles
(4)
,
Christian Brambilla
(5)
,
Elisabeth Brambilla
(6)
,
Aurélien Vesin
(7)
,
Jean-François Timsit
(8)
,
Pierre Hainaut
(9)
,
Yves Martinet
(10, 11)
,
J. M. Vignaud
(10, 11)
,
Frederik B. Thunnissen
(12, 13)
,
Clemens Prinsen
(12)
,
Peter J. Snijders
(13)
,
E. F. Smit
(14)
,
Gabriella Sozzi
(15)
,
Luca Roz
(15)
,
Angela Risch
(16)
,
Heinrich D. Becker
(17)
,
J. Stuart Elborn
(18)
,
N. D. Magee
(18)
,
Luis M. Montuenga
(19)
,
Maria J. Pajares
(19)
,
M. D. Lozano
(19)
,
Ken J. O'Byrne
(20)
,
D. J. Harrison
(21)
,
Jacek Niklinski
(22)
,
Adrian Cassidy
(2)
,
Non Renseigné
1
Canc Res Ctr
2 Canc Res Ctr, Roy Castle Lung Canc Res Programme
3 Sch Canc Studies
4 Dept Cytopathol
5 INSERM U823, équipe 2 (Bases Moléculaires de la Progression des Cancers du Poumon)
6 INSERM U823, équipe 2 (Bases Moléculaires de la Progression des Cancers du Poumon)
7 INSERM U823 - Institut d'oncologie/développement Albert Bonniot de Grenoble
8 INSERM U823, équipe 11 (Epidémiologie des cancers et des affections graves)
9 Int Agcy Res Canc
10 CRB Nancy - Centre de Ressources Biologiques - [Nancy]
11 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
12 Dept Pathol
13 Med Ctr, Dept Pathol
14 Med Ctr, Dept Pulmonol
15 Dept Expt Oncol & Labs
16 DKFZ - German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg]
17 Thoraxklin Heidelberg Univ
18 Ctr Infect & Immun, Resp Med Res Grp
19 Ctr Appl Med Res CIMA
20 St James Hosp
21 Queens Med Res Inst, Div Pathol
22 Dept Thorac Surg
2 Canc Res Ctr, Roy Castle Lung Canc Res Programme
3 Sch Canc Studies
4 Dept Cytopathol
5 INSERM U823, équipe 2 (Bases Moléculaires de la Progression des Cancers du Poumon)
6 INSERM U823, équipe 2 (Bases Moléculaires de la Progression des Cancers du Poumon)
7 INSERM U823 - Institut d'oncologie/développement Albert Bonniot de Grenoble
8 INSERM U823, équipe 11 (Epidémiologie des cancers et des affections graves)
9 Int Agcy Res Canc
10 CRB Nancy - Centre de Ressources Biologiques - [Nancy]
11 NGERE - Nutrition-Génétique et Exposition aux Risques Environnementaux
12 Dept Pathol
13 Med Ctr, Dept Pathol
14 Med Ctr, Dept Pulmonol
15 Dept Expt Oncol & Labs
16 DKFZ - German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg]
17 Thoraxklin Heidelberg Univ
18 Ctr Infect & Immun, Resp Med Res Grp
19 Ctr Appl Med Res CIMA
20 St James Hosp
21 Queens Med Res Inst, Div Pathol
22 Dept Thorac Surg
Christian Brambilla
- Function : Author
- PersonId : 932361
Jean-François Timsit
- Function : Author
- PersonId : 758651
- ORCID : 0000-0002-6063-7383
- IdRef : 077116313
Non Renseigné
- Function : Author
Abstract
The European Early Lung Cancer (EUELC) project aims to determine if specific genetic alterations occurring in lung carcinogenesis are detectable in the respiratory epithelium. In order to pursue this objective, nonsmall cell lung cancer (NSCLC) patients with a very high risk of developing progressive lung cancer were recruited from 12 centres in eight European countries: France, Germany, southern Ireland, Italy, the Netherlands, Poland, Spain and the UK. In addition, NSCLC patients were followed up every 6 months for 36 months. A European Bronchial Tissue Bank was set up at the University of Liverpool (Liverpool, UK) to optimise the use of biological specimens. The molecular-pathological investigations were subdivided into specific work packages that were delivered by EUELC Partners. The work packages encompassed mutational analysis, genetic instability, methylation profiling, expression profiling utilising immunohistochemistry and chip-based technologies, as well as in-depth analysis of FHIT and RARbeta genes, the telomerase catalytic subunit hTERT and genotyping of susceptibility genes in specific pathways. The EUELC project engendered a tremendous collaborative effort, and it enabled the EUELC Partners to establish protocols for assessing molecular biomarkers in early lung cancer with the view to using such biomarkers for early diagnosis and as intermediate end-points in future chemopreventive programmes.